Express Mail No. EV514612488US

Date of Deposit: April 12, 2005

Attorney Reference Number 7037-70886-01

Application Number: Currently unknown

Amendments to the Claims

1. (original) A method for decreasing depression by inhibiting the activity of N-type

calcium channel.

WDN/SLR:dm 04/12/05 371980

**PATENT** 

2. (currently amended) The method for decreasing depression as set forth in of claim 1,

wherein the N-type calcium channel method is an inhibiting the activity of alpha 1B of N-

type calcium channel.

3. (currently amended) The method for decreasing depression as set forth in claim 1,

wherein the inhibiting the N-type calcium channel is accomplished by administering

treating a substance that acts working specifically upon the toward N-type calcium

channel to inhibit its activity.

4. (currently amended) The method for decreasing depression as set forth in claim 1,

wherein the inhibiting the N-type channel is accomplished by administering treating an

antibody combining that specifically binds with the N-type calcium channel.

5. (currently amended) The method for decreasing depression as set forth in claim 1,

wherein the inhibiting the N-type calcium channel is accomplished by suppressing the

transcription of a gene encoding the N-type calcium channel.

6. (currently amended) The method for decreasing depression as set forth in claim 1,

wherein the inhibiting the N-type calcium channel is accomplished by suppressing the

translation of a transcribed N-type calcium channel gene.

7. (original) An anti-depression agent containing a N-type calcium channel inhibitor as an

effective ingredient.

8. (currently amended) The anti-depression agent as set forth in claim 7, wherein the anti-

depression agent contains the an N-type calcium channel alpha 1B inhibitor as an effective

Page 3 of 5

Express Mail No. EV514612488US

Date of Deposit: April 12, 2005

Attorney Reference Number 7037-70886-01

Application Number: Currently unknown

ingredient.

WDN/SLR:dm 04/12/05 371980

**PATENT** 

9. (currently amended) The anti-depression agent as set forth in claim 7, wherein the N-type

calcium channel inhibitor is selected from a group consisting of a compound acting

specifically upon an N-type calcium channel to inhibit its activity, an antibody combining

specifically with the N-type calcium channel, a substance inhibiting the transcription of a

gene encoding the N-type calcium channel, or and a substance inhibiting the translation of

a transcribed N-type calcium channel gene.

10. (canceled)

The A screening method for the an anti-depression agent, 11. (currently amended)

comprising as set forth in claim 10, wherein the method is comprised of the following

steps:

1) Oobtaining a transformant by transfecting host cells with a vector containing an alpha

1B structural gene and a reporter gene;

2) Cculturing the above transformant along with a test sample for screening; and

3)-Mmeasuring the expression of the reporter gene, wherein decreased expression of the

reporter gene indicates that expression of the alpha 1B structural gene is decreased

and that the test sample is an anti-depression agent.

Page 4 of 5